Armata Pharmaceuticals IPO

1/10/2023

IPO

$30,000,000

Armata intends to use the net proceeds from this transaction to continue clinical development of AP-PA02 and AP-SA02. Additionally, these funds will finance the completion of an advanced biologics cGMP manufacturing facility with the technology and capacity to support production of complex multi-component phage therapeutics.

Private & Independent

Biopharmaceutical

4503 Glencoe Avenue
Marina del Rey,, CA 90292
USA

A Purposeful, Precise and Powerful Approach to Address the Global Antibiotic Resistance Crisis. Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections. Antibiotic overuse has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which common infections can be serious or life-threatening. Additionally, the use of broad-spectrum antibiotics is known for disrupting the ecology of the human microbiome, leading to disease.